CCL2 and chronic kidney disease: The above effects of Tan IIA may be related to the inhibition of fibroblast recruitment to the kidney by inhibiting the expression of TGF-β1 and MCP-1, suggesting that Tan IIA may be a new therapy to prevent the progression of CKD after AKI.